Toll-like receptor signaling and its role in cell-mediated immunity
Innate immunity is the first defense system against invading pathogens. Toll-like receptors
(TLRs) are well-defined pattern recognition receptors responsible for pathogen recognition …
(TLRs) are well-defined pattern recognition receptors responsible for pathogen recognition …
Role of Bruton's tyrosine kinase in B cells and malignancies
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
GW Wright, JD Phelan, ZA Coulibaly, S Roulland… - Cancer cell, 2020 - cell.com
The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
Genetics and pathogenesis of diffuse large B-cell lymphoma
R Schmitz, GW Wright, DW Huang… - New England journal …, 2018 - Mass Medical Soc
Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …
a clinically and genetically heterogeneous disease that is further classified into …
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
Diffuse large B-cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
The role of TLRs in anti-cancer immunity and tumor rejection
In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although
chronic inflammation has been described as one of the hallmarks of cancer, acute …
chronic inflammation has been described as one of the hallmarks of cancer, acute …
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like
(ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC …
(ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC …